Nirsevimab Administration  
Visual Guide

Is it October 1 through March 31, or have regional experts or health authorities recommended nirsevimab administration currently?

Yes

Is the patient < 8 months of age today?

Yes

Did the mother of this patient receive the RSV vaccine while pregnant?

Yes

Was the infant born within 14 days of maternal RSV vaccine administration?

Yes

Generally Not Recommended

No

Recommended

Nirsevimab 200 mg

No

Recommended

Has the patient received 1 or more doses of palivizumab in the current RSV season?

No

Recommended

Has the patient received a previous dose of nirsevimab in the current RSV season (eg. in the newborn nursery)?

Yes

Has the patient received 1 or more doses of palivizumab in the current RSV season?

Yes

What is the patient’s current weight (today)?

< 5 kg

Nirsevimab 50 mg/0.5 mL

≥ 5 kg

Nirsevimab 100 mg/mL

No

Yes

Has 30 days elapsed since the last dose?

Yes

Wait until 30 days elapse.

No

Has the patient 8–19 months old today and meet the high risk criteriaa?

Yes

No or Unknown

Recommended

Nirsevimab 200 mg

No

Recommended

Not Recommended

Not Recommended

Not Recommended

Not Recommended

Not Recommended

Is the patient 8–19 months old today and meet the high risk criteriaa?

Mothe
At the time of administration, affirm the 7 rights to reduce errors:

1. Right patient
2. Right time (age, in RSV season)
3. Right immunization (correct medication)
4. The right dosage (based on weight)
5. The right route, needle length, and technique
6. **Right site**

**Intramuscular (IM) injection**

Use a 22–25 gauge needle. Choose the injection site and needle length that is appropriate to the person’s age and body mass.

<table>
<thead>
<tr>
<th>Age</th>
<th>Needle length</th>
<th>Injection site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Newborns (1st 28 days)</td>
<td>⅝”c</td>
<td>Anterolateral thigh muscle</td>
</tr>
<tr>
<td>Infants (1–12 months)</td>
<td>1”</td>
<td>Anterolateral thigh muscle</td>
</tr>
<tr>
<td>Toddlers (1–2 years)</td>
<td>1–1¼”</td>
<td>Anterolateral thigh musclee</td>
</tr>
<tr>
<td></td>
<td>⅝”d–1”</td>
<td>Deltoid muscle of arm</td>
</tr>
</tbody>
</table>

7. The right documentation

c. If skin is stretched tightly and subcutaneous tissues are not bunched.
d. Alternate needle lengths may be used if the skin is stretched tightly and subcutaneous tissues are not bunched, as follows: a) a ⅝” needle in toddlers, children, and patients weighing less than 150 lbs (less than 60 kg) for IM injection in the deltoid muscle only, or b) a 1” needle for administration in the thigh muscle for adults of any weight.
e. Preferred site

**NOTE:** Always refer to the package insert included with each biologic for complete vaccine administration information. CDC’s Advisory Committee on Immunization Practices (ACIP) recommendations for the particular vaccine should be reviewed as well. Access the ACIP recommendations at [www.immunize.org/acip](http://www.immunize.org/acip).